A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non alcoholic Fatty Liver Disease (NAFLD) (MAESTRO NAFLD-1)

Clinical Trial

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The primary goal of this study is to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo.

Information

Principal Investigator	Gregg Wendorff, MD
Co-PI
Sponsor
Type of Trial	Prospective/Interventional

Ask

We are here to help. If you have any question about your participation in a clinical trial, please contact us.

Participate

To participate in existing clinical trials, please contact us

A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non alcoholic Fatty Liver Disease (NAFLD) (MAESTRO NAFLD-1)

Study Status:

Contact Information:

Study Purpose

Information

Ask

Participate

Donate

Useful Links

For Research Participants

About Us

News & Views